F10 and myocardial infarction: Rivaroxaban, an oral anticoagulant that directly and selectively inhibits factor Xa, has been proven to reduce CVDs mortality and the risk of stroke and myocardial infarction (MI) in patients with acute coronary syndromes (Mega et al., 2012).